Decongestion therapy with tolvaptan in acute heart failure patients with renal dysfunction was tested in a randomized study.

Treatment with tolvaptan achieved more urine output and dyspnea relief compared with conventional therapy.

There was no significant difference in rate of worsening renal function between groups.

Tolvaptan could be an option for treating acute heart failure patients with renal dysfunction.